Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jun;63(3):152-7.
doi: 10.1007/s13224-013-0419-x. Epub 2013 Jun 21.

Origin of ovarian cancer: molecular profiling

Dilip Kumar Dutta  1 , Indranil Dutta  1
Affiliations
Review

Origin of ovarian cancer: molecular profiling

Dilip Kumar Dutta et al. J Obstet Gynaecol India. 2013 Jun.

Abstract

This is a review on the transition from our empirical approach to treat ovarian cancer to a specific treatment based on molecular signature. We have reviewed not only the evidence-based medicine focused on the origin and tumor morphology of ovarian cancer but also the molecular signature era based on molecular phenotyping of the tumor and its microenvironment, which influences the direct targeted therapy. Evidence-based medicine has shown that the targeted therapy studies are mainly biomarker driven, more focused, and hence treat only those patients who have the underlying molecular abnormality. This molecular abnormality is the target of the drug, leading to higher rates of response. These findings will carry important implications for screening, detection, and treatment of ovarian cancer in the future.

Keywords: Molecular profiling; Ovarian cancer; Targeted therapy.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Type I ovarian cancer
Fig. 2
Fig. 2
Key signaling pathways involved in Type I endom. Ca
Fig. 3
Fig. 3
Type II ovarian cancer
Fig. 4
Fig. 4
Model for ovarian tumorigenesis
See this image and copyright information in PMC

References

    1. Reiss A, Walter H, lieb G. On the original ovarian and endometrial cancer: molecular profiling of gynecologic cancer. Recent Adv Gyne Oncol. 2010;10:134–144.
    1. Fukumoto M, Nakayama K. Ovarian epithelial tumors of low malignant potential: Are they precursors of ovarian carcinoma? Pathol Int. 2006;56:233–239. doi: 10.1111/j.1440-1827.2006.01960.x. - DOI - PubMed
    1. Gotlieb WH, Friedman E, Bar-Sade RB, et al. Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors. J Natl Cancer Inst. 1998;90:995–1000. doi: 10.1093/jnci/90.13.995. - DOI - PubMed
    1. Ho CL, Kurman RJ, Dehari R, et al. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res. 2004;64:6915–6918. doi: 10.1158/0008-5472.CAN-04-2067. - DOI - PubMed
    1. Kurman RJ, Shih Ie M. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol. 2008;27:151–160. - PMC - PubMed

LinkOut - more resources